{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:24:30Z","timestamp":1778336670876,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,8]]},"DOI":"10.7759\/cureus.44924","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T23:35:41Z","timestamp":1694216141000},"source":"Crossref","is-referenced-by-count":6,"title":["Advancements in Diagnostic and Therapeutic Interventions of Non-alcoholic Fatty Liver Disease: A Literature Review"],"prefix":"10.7759","author":[{"given":"Ahtshamullah","family":"Chaudhry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawad","family":"Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima","family":"Batool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghulam","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riwad","family":"Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96966-5","article-title":"Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD","volume":"11","author":"Pantano L","year":"2021","unstructured":"Pantano L, Agyapong G, Shen Y, et al.. Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. Sci Rep. 2021, 11:18045. 10.1038\/s41598-021-96966-5","journal-title":"Sci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020468","article-title":"Non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and non-viral hepatocarcinoma: pathophysiological mechanisms and new therapeutic strategies","volume":"11","author":"Vetrano E","year":"2023","unstructured":"Vetrano E, Rinaldi L, Mormone A, et al.. Non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and non-viral hepatocarcinoma: pathophysiological mechanisms and new therapeutic strategies. Biomedicines. 2023, 11:468. 10.3390\/biomedicines11020468","journal-title":"Biomedicines"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/biology9100338","article-title":"The nuclear envelope in lipid metabolism and pathogenesis of NAFLD","volume":"9","author":"\u00d6stlund C","year":"2020","unstructured":"\u00d6stlund C, Hernandez-Ono A, Shin JY. The nuclear envelope in lipid metabolism and pathogenesis of NAFLD. Biology (Basel). 2020, 9:338. 10.3390\/biology9100338","journal-title":"Biology (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper P","year":"2021","unstructured":"Kasper P, Martin A, Lang S, K\u00fctting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021, 110:921-37. 10.1007\/s00392-020-01709-7","journal-title":"Clin Res Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher G","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021, 18:599-612. 10.1038\/s41575-021-00448-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee QM","year":"2013","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013, 10:330-44. 10.1038\/nrgastro.2013.41","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1055\/a-1957-8540","article-title":"Current challenges and future direction in surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease","volume":"43","author":"Cholankeril G","year":"2023","unstructured":"Cholankeril G, El-Serag HB. Current challenges and future direction in surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2023, 43:89-99. 10.1055\/a-1957-8540","journal-title":"Semin Liver Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-022-01932-1","article-title":"SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum","volume":"58","author":"Kamada Y","year":"2023","unstructured":"Kamada Y, Nakamura T, Isobe S, et al.. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. J Gastroenterol. 2023, 58:79-97. 10.1007\/s00535-022-01932-1","journal-title":"J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.030","article-title":"Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum","volume":"73","author":"Glass O","year":"2020","unstructured":"Glass O, Filozof C, Noureddin M, et al.. Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. J Hepatol. 2020, 73:680-93. 10.1016\/j.jhep.2020.04.030","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2010.04.003","article-title":"Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes","volume":"43","author":"Narasimhan S","year":"2010","unstructured":"Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, Balasubramanyam M. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem. 2010, 43:815-21. 10.1016\/j.clinbiochem.2010.04.003","journal-title":"Clin Biochem"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2203082","article-title":"Pathophysiological mechanisms and clinical evidence of relationship between nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease","volume":"22","author":"Galiero R","year":"2021","unstructured":"Galiero R, Caturano A, Vetrano E, et al.. Pathophysiological mechanisms and clinical evidence of relationship between nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. Rev Cardiovasc Med. 2021, 22:755-68. 10.31083\/j.rcm2203082","journal-title":"Rev Cardiovasc Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01281-6","article-title":"Managing NAFLD in type 2 diabetes: the effect of lifestyle interventions, a narrative review","volume":"37","author":"Parry SA","year":"2020","unstructured":"Parry SA, Hodson L. Managing NAFLD in type 2 diabetes: the effect of lifestyle interventions, a narrative review. Adv Ther. 2020, 37:1381-406. 10.1007\/s12325-020-01281-6","journal-title":"Adv Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/nu14091813","article-title":"Effect of a six-month lifestyle intervention on the physical activity and fitness status of adults with NAFLD and metabolic syndrome","volume":"14","author":"Mascar\u00f3 CM","year":"2022","unstructured":"Mascar\u00f3 CM, Bouzas C, Montemayor S, et al.. Effect of a six-month lifestyle intervention on the physical activity and fitness status of adults with NAFLD and metabolic syndrome. Nutrients. 2022, 14:1813. 10.3390\/nu14091813","journal-title":"Nutrients"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/nu12113472","article-title":"Physiopathology of lifestyle interventions in non-alcoholic fatty liver disease (NAFLD)","volume":"12","author":"Carneros D","year":"2020","unstructured":"Carneros D, L\u00f3pez-Lluch G, Bustos M. Physiopathology of lifestyle interventions in non-alcoholic fatty liver disease (NAFLD). Nutrients. 2020, 12:3472. 10.3390\/nu12113472","journal-title":"Nutrients"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415489","article-title":"Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment","volume":"23","author":"Guo X","year":"2022","unstructured":"Guo X, Yin X, Liu Z, Wang J. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci. 2022, 23:15489. 10.3390\/ijms232415489","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/nu14112223","article-title":"Effect of dietary and lifestyle interventions on the amelioration of NAFLD in patients with metabolic syndrome: the FLIPAN study","volume":"14","author":"Montemayor S","year":"2022","unstructured":"Montemayor S, Bouzas C, Mascar\u00f3 CM, et al.. Effect of dietary and lifestyle interventions on the amelioration of NAFLD in patients with metabolic syndrome: the FLIPAN study. Nutrients. 2022, 14:2223. 10.3390\/nu14112223","journal-title":"Nutrients"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i19.2083","article-title":"Mediterranean diet and nonalcoholic fatty liver disease","volume":"24","author":"Anania C","year":"2018","unstructured":"Anania C, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol. 2018, 24:2083-94. 10.3748\/wjg.v24.i19.2083","journal-title":"World J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg H","year":"2017","unstructured":"Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017, 14:32-42. 10.1038\/nrgastro.2016.147","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1716333","article-title":"Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected?","volume":"29","author":"Michel M","year":"2020","unstructured":"Michel M, Schattenberg JM. Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease) - how are clinical trials affected?. Expert Opin Investig Drugs. 2020, 29:93-7. 10.1080\/13543784.2020.1716333","journal-title":"Expert Opin Investig Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3386","article-title":"NAFLD in type 2 diabetes mellitus: Still many challenging questions","volume":"37","author":"Cernea S","year":"2021","unstructured":"Cernea S, Raz I. NAFLD in type 2 diabetes mellitus: Still many challenging questions. Diabetes Metab Res Rev. 2021, 37:e3386. 10.1002\/dmrr.3386","journal-title":"Diabetes Metab Res Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03295-x","article-title":"Applications of quantitative systems pharmacology (QSP) in drug development for NAFLD and NASH and its regulatory application","volume":"39","author":"Siler SQ","year":"2022","unstructured":"Siler SQ. Applications of quantitative systems pharmacology (QSP) in drug development for NAFLD and NASH and its regulatory application. Pharm Res. 2022, 39:1789-802. 10.1007\/s11095-022-03295-x","journal-title":"Pharm Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi CK","year":"2022","unstructured":"Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 2022, 126:154925. 10.1016\/j.metabol.2021.154925","journal-title":"Metabolism"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic landscape for NAFLD in 2020","volume":"158","author":"Neuschwander-Tetri BA","year":"2020","unstructured":"Neuschwander-Tetri BA. Therapeutic landscape for NAFLD in 2020. Gastroenterology. 2020, 158:1984-1998.e3. 10.1053\/j.gastro.2020.01.051","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13464","article-title":"The effect of pharmacological treatment and lifestyle modification in patients with nonalcoholic fatty liver disease: An umbrella review of meta-analyses of randomized controlled trials","volume":"23","author":"Cho K","year":"2022","unstructured":"Cho K, Park S, Koyanagi A, et al.. The effect of pharmacological treatment and lifestyle modification in patients with nonalcoholic fatty liver disease: An umbrella review of meta-analyses of randomized controlled trials. Obes Rev. 2022, 23:e13464. 10.1111\/obr.13464","journal-title":"Obes Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108984","article-title":"Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial","volume":"178","author":"Della Pepa G","year":"2021","unstructured":"Della Pepa G, Russo M, Vitale M, et al.. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res Clin Pract. 2021, 178:108984. 10.1016\/j.diabres.2021.108984","journal-title":"Diabetes Res Clin Pract"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01129-y","article-title":"Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD","volume":"13","author":"Johnson ND","year":"2021","unstructured":"Johnson ND, Wu X, Still CD, et al.. Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. Clin Epigenetics. 2021, 13:152. 10.1186\/s13148-021-01129-y","journal-title":"Clin Epigenetics"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00395","article-title":"Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis","volume":"7","author":"Garcia-Martinez I","year":"2020","unstructured":"Garcia-Martinez I, Alen R, Rada P, Valverde AM. Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis. Front Med (Lausanne). 2020, 7:395. 10.3389\/fmed.2020.00395","journal-title":"Front Med (Lausanne)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-014-9573-1","article-title":"Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis","volume":"8","author":"Ferraioli G","year":"2014","unstructured":"Ferraioli G, Tinelli C, Lissandrin R, et al.. Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis. Hepatol Int. 2014, 8:576-81. 10.1007\/s12072-014-9573-1","journal-title":"Hepatol Int"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15738","article-title":"Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis","volume":"51","author":"Carlsson B","year":"2020","unstructured":"Carlsson B, Lind\u00e9n D, Brol\u00e9n G, Liljeblad M, Bjursell M, Romeo S, Loomba R. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2020, 51:1305-20. 10.1111\/apt.15738","journal-title":"Aliment Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez R","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011, 54:1082-90. 10.1002\/hep.24452","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1948","article-title":"Relationship between controlled attenuated parameter and magnetic resonance imaging-proton density fat fraction for evaluating hepatic steatosis in patients with NAFLD","volume":"6","author":"An Z","year":"2022","unstructured":"An Z, Liu Q, Zeng W, et al.. Relationship between controlled attenuated parameter and magnetic resonance imaging-proton density fat fraction for evaluating hepatic steatosis in patients with NAFLD. Hepatol Commun. 2022, 6:1975-86. 10.1002\/hep4.1948","journal-title":"Hepatol Commun"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.005","article-title":"MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice","volume":"65","author":"Dulai PS","year":"2016","unstructured":"Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. J Hepatol. 2016, 65:1006-16. 10.1016\/j.jhep.2016.06.005","journal-title":"J Hepatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.09.041","article-title":"Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis","volume":"20","author":"Andersson A","year":"2022","unstructured":"Andersson A, Kelly M, Imajo K, et al.. Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis. Clin Gastroenterol Hepatol. 2022, 20:2451-2461.e3. 10.1016\/j.cgh.2021.09.041","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-022-00377-8","article-title":"Non-invasive diagnosis and staging of non-alcoholic fatty liver disease","volume":"21","author":"Kechagias S","year":"2022","unstructured":"Kechagias S, Ekstedt M, Simonsson C, Nasr P. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones (Athens). 2022, 21:349-68. 10.1007\/s42000-022-00377-8","journal-title":"Hormones (Athens)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-021-06922-6","article-title":"Impact of a pilot structured mobile technology based lifestyle intervention for patients with nonalcoholic fatty liver disease","volume":"67","author":"Tincopa MA","year":"2022","unstructured":"Tincopa MA, Lyden A, Wong J, Jackson EA, Richardson C, Lok AS. Impact of a pilot structured mobile technology based lifestyle intervention for patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2022, 67:481-91. 10.1007\/s10620-021-06922-6","journal-title":"Dig Dis Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i13.3777","article-title":"Current pharmacological therapies for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"21","author":"Takahashi Y","year":"2015","unstructured":"Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol. 2015, 21:3777-85. 10.3748\/wjg.v21.i13.3777","journal-title":"World J Gastroenterol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-3760","article-title":"Non-alcoholic fatty liver diseases: current challenges and future directions","volume":"9","author":"Roeb E","year":"2021","unstructured":"Roeb E. Non-alcoholic fatty liver diseases: current challenges and future directions. Ann Transl Med. 2021, 9:726. 10.21037\/atm-20-3760","journal-title":"Ann Transl Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/169138-advancements-in-diagnostic-and-therapeutic-interventions-of-non-alcoholic-fatty-liver-disease-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:34Z","timestamp":1707509134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/169138-advancements-in-diagnostic-and-therapeutic-interventions-of-non-alcoholic-fatty-liver-disease-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.44924","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}